Anthropometric Measurements as Predictors of Low Birth Weight Among Tanzanian Neonates: A Hospital-Based Study
November 7, 2025
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
Ocrevus
Synonyms :
ocrelizumab
Class :
Monoclonal Antibodies, Multiple Sclerosis Treatments
Brand Name :
Ocrevus
Synonyms :
ocrelizumab
Class :
Monoclonal Antibodies, Multiple Sclerosis Treatments
Dosage Forms & StrengthsÂ
Solution Â
30mg/mlÂ
For initial two doses: administer dose of 300 mg intravenously one time and repeat the dose two weeks later
For subsequent dose: administer dose of 600 mg intravenously each six months
Dosage Modifications
As Mild-to-moderate:
Decrease the infusion rate to half the rate at the onset of the infusion reaction and maintain the decreased rate for minimum half an hour
As Life-threatening:
Immediately stop and discontinue forever ocrelizumab drug if there are signs of a life-threatening reaction
Dosing Considerations
For HBV screening
Perform Hepatitis B virus (HBV) screening test prior to start ocrelizumab
For Vaccinations
Administer all vaccines according to vaccination guidelines minimum 4 weeks before starting for live or live-attenuated vaccines
Safety and efficacy not determinedÂ
Refer to adult dosingÂ
When ocrelizumab is used in combination with rabies vaccine, this leads to a reduction in the rabies vaccine effects through the process of pharmacodynamic antagonism
ocrelizumab's immunosuppressive properties lessen the impact of the influenza A (H5N1) vaccination
By immunosuppressive effects, the both the drugs action either decreases and results in risk of infection.
may have an increased immunosuppressive effect when combined with ocrelizumab
may have an increased immunosuppressive effect when combined with ocrelizumab
may have an increased immunosuppressive effect when combined with ocrelizumab
may have an increased immunosuppressive effect when combined with ocrelizumab
may have an increased immunosuppressive effect when combined with ocrelizumab
It may diminish the effects when combined with rozanolixizumab by receptor binding competition
ocrelizumab: they may increase the immunosuppressive effect of immunostimulants
ocrelizumab: they may increase the immunosuppressive effect of immunostimulants
ocrelizumab: they may increase the immunosuppressive effect of immunostimulants
ocrelizumab: they may increase the immunosuppressive effect of immunostimulants
ocrelizumab: they may increase the immunosuppressive effect of immunostimulants
ocrelizumab: they may increase the immunosuppressive effect of selective immunosuppressants
ocrelizumab: they may increase the immunosuppressive effect of selective immunosuppressants
ocrelizumab: they may increase the immunosuppressive effect of selective immunosuppressants
may increase the immunosuppressive effect of immunosuppressants
may increase the immunosuppressive effect of immunosuppressants
may increase the immunosuppressive effect of immunosuppressants
may increase the immunosuppressive effect of Immunosuppressive agents
may increase the adverse effect of Immunosuppressants
may increase the immunosuppressive effect of Immunosuppressants
Actions and SpectrumÂ
ocrelizumab targets a specific protein known as CD20 found on surface of B cells. Â
By binding to CD20 ocrelizumab selectively depletes B cells and leads to reduction in their numbers in bloodstream and affected tissues.Â
Frequency defined Â
1-10%Â
Diarrhea (6%)Â
Pain in extremity (5%)Â
Peripheral edema (6%)Â
Lower respiratory tract infections (8-10%)Â
Cough (7%)Â
Depression (8%)Â
Back pain (6%)Â
Herpes virus-associated infections (5-6%)Â
>10%Â
Skin infections (14%)Â
Decreased neutrophil counts (13%)Â
Upper respiratory tract infections (40-49%)Â
Infusion-related reactions (34-40%)Â
Post marketing ReportsÂ
Serious herpes infections and progressive multifocal leukoencephalopathyÂ
Immune-mediated colitisÂ
Black Box WarningÂ
None Â
Contraindication/Caution:Â
Ocrelizumab should not be used with known hypersensitivity or severe allergic reactions.Â
Pregnancy consideration:Â
Pregnancy category: N/AÂ
Lactation: Excretion into human milk is unknown Â
Pregnancy Categories:        Â
Pharmacology Â
Ocrelizumab aids in regulating the immune response and decreases the production of autoantibodies which mistakenly attack the tissues in autoimmune diseases.Â
PharmacodynamicsÂ
Its ability is to decrease B cell production and autoantibody production results in an overall anti-inflammatory effect in autoimmune conditions like multiple sclerosis and rheumatoid arthritis.Â
PharmacokineticsÂ
Absorption  Â
Rapidly absorbed into the bloodstream after intravenous administration. Â
DistributionÂ
ocrelizumab is distributes throughout the body.Â
MetabolismÂ
ocrelizumab are not broken down into smaller components by the liver.Â
Elimination and excretionÂ
route of excretion for ocrelizumab is via the reticuloendothelial system.Â
The terminal half-life is 26 days.Â
AdministrationÂ
ocrelizumab is given as an intravenous (IV) infusion. Â
Patient information leafletÂ
Generic Name: ocrelizumabÂ
Why do we use ocrelizumab?Â
ocrelizumab treats the relapsing forms of Multiple sclerosis which can reduce the frequency of relapses and slow down disease progression.Â
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
